We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Strength Seen in Oculis Holding AG (OCS): Can Its 6.7% Jump Turn into More Strength?
Read MoreHide Full Article
Oculis Holding AG (OCS - Free Report) shares soared 6.7% in the last trading session to close at $17.73. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 6.9% loss over the past four weeks.
The sudden price rise can be attributed to growing investor optimism surrounding the company’s three product candidates, OCS-01, which is being developed in late-stage studies for treating diabetic macular edema, privosegtor (OCS-05), which is in mid-stage development for acute optic neuritis and licaminlimab (OCS-02), which is being developed with a genotype-based approach to drive personalized medicine in dry eye disease.
This company is expected to post quarterly loss of $0.50 per share in its upcoming report, which represents a year-over-year change of +9.1%. Revenues are expected to be $0.25 million, down 1.6% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Oculis Holding AG, the consensus EPS estimate for the quarter has been revised 7.3% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on OCS going forward to see if this recent jump can turn into more strength down the road.
Oculis Holding AG belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Incyte (INCY - Free Report) , closed the last trading session 2.1% lower at $84.73. Over the past month, INCY has returned 1.8%.
Incyte's consensus EPS estimate for the upcoming report has changed +0.4% over the past month to $1.64. Compared to the company's year-ago EPS, this represents a change of +53.3%. Incyte currently boasts a Zacks Rank of #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Strength Seen in Oculis Holding AG (OCS): Can Its 6.7% Jump Turn into More Strength?
Oculis Holding AG (OCS - Free Report) shares soared 6.7% in the last trading session to close at $17.73. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 6.9% loss over the past four weeks.
The sudden price rise can be attributed to growing investor optimism surrounding the company’s three product candidates, OCS-01, which is being developed in late-stage studies for treating diabetic macular edema, privosegtor (OCS-05), which is in mid-stage development for acute optic neuritis and licaminlimab (OCS-02), which is being developed with a genotype-based approach to drive personalized medicine in dry eye disease.
This company is expected to post quarterly loss of $0.50 per share in its upcoming report, which represents a year-over-year change of +9.1%. Revenues are expected to be $0.25 million, down 1.6% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Oculis Holding AG, the consensus EPS estimate for the quarter has been revised 7.3% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on OCS going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Oculis Holding AG belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Incyte (INCY - Free Report) , closed the last trading session 2.1% lower at $84.73. Over the past month, INCY has returned 1.8%.
Incyte's consensus EPS estimate for the upcoming report has changed +0.4% over the past month to $1.64. Compared to the company's year-ago EPS, this represents a change of +53.3%. Incyte currently boasts a Zacks Rank of #3 (Hold).